Pharma & Biotech
FSD Pharma throws resources behind legacy anti-inflammatory drug as potential coronavirus therapy
Acasti Pharma eyeing FDA meeting as it continues to advance heart disease candidate CaPre
XPhyto Therapeutics, the science-based cannabis group, advancing German goals with three year supply deal
Only registered members can use this feature.
Copyright © Proactive Investors 2020.
All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC.